MA34556B1 - Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger - Google Patents

Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Info

Publication number
MA34556B1
MA34556B1 MA35785A MA35785A MA34556B1 MA 34556 B1 MA34556 B1 MA 34556B1 MA 35785 A MA35785 A MA 35785A MA 35785 A MA35785 A MA 35785A MA 34556 B1 MA34556 B1 MA 34556B1
Authority
MA
Morocco
Prior art keywords
fusioned
triazoles
prophylaxis
treatment
cognitive disorders
Prior art date
Application number
MA35785A
Other languages
English (en)
French (fr)
Inventor
Tatsuki Koike
Minoru Nakamura
Yoshihide Tomata
Takafumi Takai
Yasutaka Hoashi
Yuichi Kajita
Tetsuya Tsukamoto
Makoto Kamata
Original Assignee
Takeda Pharmaceutcal Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45094181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34556(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutcal Company Ltd filed Critical Takeda Pharmaceutcal Company Ltd
Publication of MA34556B1 publication Critical patent/MA34556B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA35785A 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger MA34556B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010197064 2010-09-02
JP2011143548 2011-06-28
PCT/JP2011/070419 WO2012029991A1 (en) 2010-09-02 2011-09-01 Fused triazoles for the treatment or prophylaxis of mild cognitive impairment

Publications (1)

Publication Number Publication Date
MA34556B1 true MA34556B1 (fr) 2013-09-02

Family

ID=45094181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35785A MA34556B1 (fr) 2010-09-02 2011-09-01 Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger

Country Status (22)

Country Link
US (3) US8822699B2 (enExample)
EP (1) EP2611805A1 (enExample)
JP (1) JP5871909B2 (enExample)
KR (1) KR20130139895A (enExample)
CN (1) CN103249733A (enExample)
AR (1) AR082865A1 (enExample)
AU (1) AU2011296887A1 (enExample)
BR (1) BR112013004746A2 (enExample)
CA (1) CA2809779A1 (enExample)
CL (1) CL2013000575A1 (enExample)
DO (1) DOP2013000051A (enExample)
EA (1) EA201390333A1 (enExample)
EC (1) ECSP13012535A (enExample)
MA (1) MA34556B1 (enExample)
MX (1) MX2013002511A (enExample)
PE (1) PE20131305A1 (enExample)
PH (1) PH12013500403A1 (enExample)
SG (1) SG187917A1 (enExample)
TW (1) TW201213327A (enExample)
UY (1) UY33586A (enExample)
WO (1) WO2012029991A1 (enExample)
ZA (1) ZA201301929B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011007756A1 (ja) * 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
US8822699B2 (en) * 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2563254C2 (ru) * 2013-07-08 2015-09-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ получения производных 7-(гетеро)арил-4,5,6,7-тетрагидро[1,2,3]триазоло[1,5-a]пиридина
PL3294743T3 (pl) * 2015-05-12 2020-03-31 Fmc Corporation Podstawione arylem związki bicykliczne jako środki chwastobójcze
US20210079182A1 (en) * 2019-09-12 2021-03-18 Dupont Electronics, Inc. Polyimide films and electronic devices
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003523345A (ja) 2000-02-17 2003-08-05 ブリストル−マイヤーズ スクイブ ファーマ カンパニー Aβタンパク質産生の阻害剤としてのスクシノイルアミノ炭素環および複素環
US7244739B2 (en) 2003-05-14 2007-07-17 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
SI1678172T1 (sl) * 2003-10-15 2010-04-30 Targacept Inc AzabicikliŽŤne spojine za lajšanje boleŽŤine in zdravljenje motenj centralnega ĹľivŽŤnega sistema
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
ATE458729T1 (de) 2004-10-26 2010-03-15 Eisai R&D Man Co Ltd Amorphe form einer zimtsäureamidverbindung
EP1976527A4 (en) 2006-01-11 2009-04-22 Merck & Co Inc CONDENSED TRIAZOL TACHYKININE RECEPTOR ANTAGONISTS
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
PL1992618T3 (pl) * 2006-03-09 2012-06-29 Eisai R&D Man Co Ltd Policykliczna pochodna cynamidowa
TW200808800A (en) 2006-05-05 2008-02-16 Astrazeneca Ab MGluR5 modulators V
EP2119719A1 (en) 2006-12-26 2009-11-18 Daiichi Sankyo Company, Limited Thiazepine derivative
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
CA2707712A1 (en) 2007-12-06 2009-06-11 Schering Corporation Gamma secretase modulators
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
JP2010197064A (ja) 2009-02-23 2010-09-09 Chugoku Electric Power Co Inc:The 直下位置測定装置
JP2012051806A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd イミダゾリルピラジン誘導体
EP2401276B1 (en) * 2009-02-26 2013-06-05 Eisai R&D Management Co., Ltd. Nitrogen-containing fused heterocyclic compounds and their use as beta amyloid production inhibitors
JP2012051807A (ja) 2009-02-26 2012-03-15 Eisai R & D Management Co Ltd アリールイミダゾール化合物
WO2011002067A1 (ja) 2009-07-02 2011-01-06 武田薬品工業株式会社 複素環化合物およびその用途
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
NZ597505A (en) 2009-07-15 2013-05-31 Janssen Pharmaceuticals Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β-類澱粉生成之化合物
WO2011016559A1 (ja) 2009-08-07 2011-02-10 武田薬品工業株式会社 複素環化合物およびその用途
JP2011143548A (ja) 2010-01-12 2011-07-28 Panasonic Corp スクリーン印刷機及びスクリーン印刷方法
US9145399B2 (en) 2010-01-15 2015-09-29 Janssen Pharmaceuticals, Inc. Substituted bicyclic triazole derivatives as gamma secretase modulators
US8822699B2 (en) * 2010-09-02 2014-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof

Also Published As

Publication number Publication date
PH12013500403A1 (en) 2013-03-25
SG187917A1 (en) 2013-04-30
KR20130139895A (ko) 2013-12-23
JP5871909B2 (ja) 2016-03-01
MX2013002511A (es) 2013-07-29
AU2011296887A1 (en) 2013-04-11
ZA201301929B (en) 2013-11-27
UY33586A (es) 2012-03-30
DOP2013000051A (es) 2013-04-30
EA201390333A1 (ru) 2013-08-30
CL2013000575A1 (es) 2013-08-23
US20130178497A1 (en) 2013-07-11
CN103249733A (zh) 2013-08-14
CA2809779A1 (en) 2012-03-08
AR082865A1 (es) 2013-01-16
US8901309B2 (en) 2014-12-02
US8822699B2 (en) 2014-09-02
WO2012029991A1 (en) 2012-03-08
EP2611805A1 (en) 2013-07-10
TW201213327A (en) 2012-04-01
US20120059030A1 (en) 2012-03-08
BR112013004746A2 (pt) 2016-06-07
ECSP13012535A (es) 2013-06-28
US20140350260A1 (en) 2014-11-27
JP2013536798A (ja) 2013-09-26
PE20131305A1 (es) 2013-10-31

Similar Documents

Publication Publication Date Title
MA34556B1 (fr) Triazoles fusionnés pour le traitement ou la prophylaxie du trouble cognitif léger
EA201491283A1 (ru) Ингибитор регулирующей апоптотические сигналы киназы
MA35623B1 (fr) Composés de 1-arylcarbonyl-4-oxypipéridine utiles pour le traitement de maladies neurodégénératives
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA34713B1 (fr) Compose bicyclique
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
MA41553B1 (fr) Sulfonylurées, composés apparentés, et leur utilisation
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA35193B1 (fr) Halogeno-alkyl-1,3 oxazines en tant qu'inhibiteurs de bace1 et/ou bace2
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
EA201890338A1 (ru) Оксадиазольные производные, пригодные в качестве ингибиторов hdac
MA37519A1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
MA35085B1 (fr) Procede de traitement d'une nephropathie induite par les produits de contraste
MA35452B1 (fr) 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
MA32911B1 (fr) Derives de benzothiazole convenant comme agents agents anticancereux
MA35096B1 (fr) Cyclopropylamines en tant qu'inhibiteurs de lsd1
MA44948A1 (fr) Inhibiteurs de bace 1
EA201692048A1 (ru) Дигидротиазин и дигидрооксазин производные, обладающие ингибирующей bace1 активностью
MA39246A1 (fr) Composé hétérocyclique fusionné
PE20180233A1 (es) Nuevos compuestos biciclicos como inhibidores duales de atx / ca
GEP20166554B (en) Nitrogenated heterocyclic compound
EA200500322A1 (ru) Соединения дигидропиразолопиридина
PE20151718A1 (es) Compuestos piridinilpirazoloquinolina
WO2014151630A3 (en) Compounds and compositions for the treatment of parasitic diseases